

## WORLD INTELLECTUAL PROPERTY ORGA International Bureau

ON



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) Internati nal Patent Classificati n <sup>5</sup> : A61K 31/585	A1	(11) Internati nal Publication Number: WO 94/08590 (43) International Publication Date: 28 April 1994 (28.04.94)
(21) International Application Number: PCT/US (22) International Filing Date: 20 October 1993 (30) Priority data: 07/963,469 20 October 1992 (20.10.9	(20.10.9	(72) Inventor; and (75) Inventor/Applicant (for US only): BERGER, Joseph, R
(60) Parent Application or Grant (63) Related by Continuation US Filed on 20 October 1992 ( (71) Applicant (for all designated States except UP PHARMACEUTICALS CORP. [US/US]; 125 way, New York, NY 10001 (US).	469 (C1 (20.10.9	(81) Designated States: AU, BR, CA, FI, HU, JP, KR, NC, NZ, PL, RU, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  Published  With international search report.  Before the expiration of the time limit for amending the

(54) Title: A METHOD FOR AMELIORATING MUSCLE WEAKNESS/WASTING IN A PATIENT INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS-TYPE 1

## (57) Abstract

A method for attenuating the HIV-associated myopathy and muscle wasting associated with infection by human immunodeficiency virus-Type 1. Administration of oxandrolone in a daily dosage of about 2.5 to about 20 milligrams is described.